Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Tumour adaptation to immune factors: old and new ideas for cancer immunotherapy
Can J Physiol Pharmacol. 2023 Sep 20. doi: 10.1139/cjpp-2023-0083. Online ahead of print.ABSTRACTThe tumour is fully functional in the zone of action of immune mediators. Moreover, the tumour needs immune system mediators to survive. "Adaptation" refers to a tumour's ability to withstand the effect of harmful elements. This gives birth to a new form of antitumour therapy: blocking tumour adaptability pathways. In this review, we will look at (i) tumour adaptation mechanisms as a result of pro-tumour immunoediting, (ii) how understanding tumour-adaptive mechanisms has led to ideas for developing cancer immunotherapies, and ...
Source: Canadian Journal of Physiology and Pharmacology - September 20, 2023 Category: Drugs & Pharmacology Authors: I Yu Malyshev O P Budanova L V Kuznetsova Source Type: research
How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery
Curr Med Chem. 2023 Sep 18. doi: 10.2174/0929867331666230918092749. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) is one of the biggest unsolved global problems of the 21st century for which there has been no definitive cure yet. Like other respiratory viruses, SARS-COV-2 triggers the host immunity dramatically, causing dysfunction in the immune system, both innate and adaptive, which is a common feature of COVID-19 patients. Evidence shows that in the early stages of COVID-19, the immune system is suppressed while it is overactive in severe p...
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Mohammad Mahdi Hajihasani Najmeh Kaffash Farkhad Ali Mahmoudi Amirhossein Sahebkar Source Type: research
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma ( & gt;5 cm)
CONCLUSIONS: In patients with unresectable multiple nodular and large HCC (single nodular diameter of >5 cm), TACE combined with target therapy and immunotherapy is safe and effective.PMID:37723998 | DOI:10.1177/15330338231200320
Source: Technology in Cancer Research and Treatment - September 19, 2023 Category: Cancer & Oncology Authors: Zhanwang Xiang Guohong Li Luwen Mu Haofan Wang Churen Zhou Huzheng Yan Mingsheng Huang Source Type: research
Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion
CONCLUSIONS: For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.PMID:37723659 | DOI:10.1111/crj.13700
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Tianyuan Li Panwen Tian Qin Huang Hao Zeng Qi Wei Yalun Li Source Type: research
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma ( & gt;5 cm)
CONCLUSIONS: In patients with unresectable multiple nodular and large HCC (single nodular diameter of >5 cm), TACE combined with target therapy and immunotherapy is safe and effective.PMID:37723998 | DOI:10.1177/15330338231200320
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Zhanwang Xiang Guohong Li Luwen Mu Haofan Wang Churen Zhou Huzheng Yan Mingsheng Huang Source Type: research
Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion
CONCLUSIONS: For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.PMID:37723659 | DOI:10.1111/crj.13700
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Tianyuan Li Panwen Tian Qin Huang Hao Zeng Qi Wei Yalun Li Source Type: research
Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: First-line immunotherapy plus chemotherapy significantly improved PFS and OS in ES-SCLC patients without liver metastases compared to chemotherapy alone. However, patients with liver metastases did not experience comparable benefits.PMID:37724893 | DOI:10.18632/aging.205035
Source: Aging - September 19, 2023 Category: Biomedical Science Authors: Yan Lin Wei Jiang Cui-Yun Su Xin-Bin Pan Source Type: research
Myelin oligodendrocyte glycoprotein antibody and N-methyl-d-aspartate receptor antibody overlapping syndrome: insights from the recent case reports
Clin Exp Immunol. 2023 Sep 19:uxad109. doi: 10.1093/cei/uxad109. Online ahead of print.ABSTRACTThe overlapping of two or more types of neural autoantibodies in one patient has increasingly been documented in recent years. The coexistence of myelin oligodendrocyte glycoprotein (MOG) and N-methyl-d-aspartate receptor (NMDAR) antibodies is most common, which leads to a unique condition known as the MOG antibody and NMDAR antibody overlapping syndrome (MNOS). Here, we have reviewed the pathogenesis, clinical manifestations, paraclinical features, and treatment of MNOS. Forty-nine patients with MNOS were included in this study....
Source: Clinical and Developmental Immunology - September 19, 2023 Category: Allergy & Immunology Authors: Bing-Qing Du Qi-Lun Lai Er-Chuang Li Meng-Ting Cai Gao-Li Fang Chun-Hong Shen Yin-Xi Zhang Mei-Ping Ding Source Type: research
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
CONCLUSIONS: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.PMID:37725593 | DOI:10.1158/1078-0432.CCR-23-0834
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Margaret Johnson April Bell Kristen L Lauing Erik Ladomersky Lijie Zhai Manon Penco-Campillo Yajas Shah Elizabeth Mauer Joanne Xiu Theodore Nicolaides Michael Drumm Kathleen McCortney Olivier Elemento Miri Kim Prashant Bommi Justin T Low Ruba Memon Jennif Source Type: research
Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion
CONCLUSIONS: For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.PMID:37723659 | DOI:10.1111/crj.13700
Source: Respiratory Care - September 19, 2023 Category: Respiratory Medicine Authors: Tianyuan Li Panwen Tian Qin Huang Hao Zeng Qi Wei Yalun Li Source Type: research
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
CONCLUSIONS: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.PMID:37725593 | DOI:10.1158/1078-0432.CCR-23-0834
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Margaret Johnson April Bell Kristen L Lauing Erik Ladomersky Lijie Zhai Manon Penco-Campillo Yajas Shah Elizabeth Mauer Joanne Xiu Theodore Nicolaides Michael Drumm Kathleen McCortney Olivier Elemento Miri Kim Prashant Bommi Justin T Low Ruba Memon Jennif Source Type: research
Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: First-line immunotherapy plus chemotherapy significantly improved PFS and OS in ES-SCLC patients without liver metastases compared to chemotherapy alone. However, patients with liver metastases did not experience comparable benefits.PMID:37724893 | DOI:10.18632/aging.205035
Source: Aging - September 19, 2023 Category: Biomedical Science Authors: Yan Lin Wei Jiang Cui-Yun Su Xin-Bin Pan Source Type: research
Myelin oligodendrocyte glycoprotein antibody and N-methyl-d-aspartate receptor antibody overlapping syndrome: insights from the recent case reports
Clin Exp Immunol. 2023 Sep 19:uxad109. doi: 10.1093/cei/uxad109. Online ahead of print.ABSTRACTThe overlapping of two or more types of neural autoantibodies in one patient has increasingly been documented in recent years. The coexistence of myelin oligodendrocyte glycoprotein (MOG) and N-methyl-d-aspartate receptor (NMDAR) antibodies is most common, which leads to a unique condition known as the MOG antibody and NMDAR antibody overlapping syndrome (MNOS). Here, we have reviewed the pathogenesis, clinical manifestations, paraclinical features, and treatment of MNOS. Forty-nine patients with MNOS were included in this study....
Source: Clinical and Developmental Immunology - September 19, 2023 Category: Allergy & Immunology Authors: Bing-Qing Du Qi-Lun Lai Er-Chuang Li Meng-Ting Cai Gao-Li Fang Chun-Hong Shen Yin-Xi Zhang Mei-Ping Ding Source Type: research
How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery
Curr Med Chem. 2023 Sep 18. doi: 10.2174/0929867331666230918092749. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) is one of the biggest unsolved global problems of the 21st century for which there has been no definitive cure yet. Like other respiratory viruses, SARS-COV-2 triggers the host immunity dramatically, causing dysfunction in the immune system, both innate and adaptive, which is a common feature of COVID-19 patients. Evidence shows that in the early stages of COVID-19, the immune system is suppressed while it is overactive in severe p...
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Mohammad Mahdi Hajihasani Najmeh Kaffash Farkhad Ali Mahmoudi Amirhossein Sahebkar Source Type: research
